C

CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765

Watchlist Manager
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Watchlist
Price: 27.34 CNY 2.01% Market Closed
Market Cap: 73.1B CNY
Have any thoughts about
CSPC Innovation Pharmaceutical Co Ltd?
Write Note

CSPC Innovation Pharmaceutical Co Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CSPC Innovation Pharmaceutical Co Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Total Equity
ÂĄ3.9B
CAGR 3-Years
11%
CAGR 5-Years
11%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Equity
ÂĄ25.8B
CAGR 3-Years
13%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Equity
ÂĄ13.7B
CAGR 3-Years
14%
CAGR 5-Years
17%
CAGR 10-Years
18%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Equity
ÂĄ42.6B
CAGR 3-Years
8%
CAGR 5-Years
13%
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Equity
ÂĄ39.4B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
14%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Equity
ÂĄ151.9m
CAGR 3-Years
-30%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CSPC Innovation Pharmaceutical Co Ltd
Glance View

Market Cap
73.1B CNY
Industry
Pharmaceuticals

Nestled in the dynamic landscape of the pharmaceutical industry, CSPC Innovation Pharmaceutical Co Ltd stands as a beacon of innovation and ambition. Evolving from its roots in traditional pharmaceutical practices, the company has carved out a niche for itself by embracing cutting-edge research and development methodologies. At the core of their operations is an unwavering commitment to creating novel drugs that target complex medical challenges. This commitment is propelled by their significant investment in state-of-the-art R&D facilities and collaborations with leading academic institutions and biotech firms. By fostering a rich pipeline of new drugs, CSPC Innovation strives to maintain its competitive edge in a rapidly changing market, driven by both pressing healthcare needs and technological advancements. The company leverages its robust distribution network to bring these innovations to market, drawing upon a diverse portfolio that includes drugs for therapeutic areas such as oncology, cardiovascular health, and metabolic disorders. Revenue generation, therefore, hinges largely on the successful commercialization of these pharmaceutical products, through both direct sales and strategic partnerships. Additionally, CSPC Innovation engages in manufacturing and selling Active Pharmaceutical Ingredients (APIs), further diversifying its income streams. By balancing risk and opportunity, the company not only aims to meet the immediate health demands of its consumer base but also positions itself to capture long-term growth within the global healthcare sector, ensuring a steady influx of revenue and sustainability for future endeavors.

Intrinsic Value
19.15 CNY
Overvaluation 30%
Intrinsic Value
Price
C

See Also

What is CSPC Innovation Pharmaceutical Co Ltd's Total Equity?
Total Equity
3.9B CNY

Based on the financial report for Sep 30, 2024, CSPC Innovation Pharmaceutical Co Ltd's Total Equity amounts to 3.9B CNY.

What is CSPC Innovation Pharmaceutical Co Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
11%

Over the last year, the Total Equity growth was -20%. The average annual Total Equity growth rates for CSPC Innovation Pharmaceutical Co Ltd have been 11% over the past three years , 11% over the past five years .

Back to Top